- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Shoaib Ugradar: AEs Associated With Teprotumumab Have Largely Been Reversible
Most of the adverse events that resulted from use of teprotumumab have been reversible, said Shoaib Ugradar, MD, UCLA Stein Eye Center Santa Monica.
Most of the adverse events that resulted from use of teprotumumab have been reversible, said Shoaib Ugradar, MD, UCLA Stein Eye Center Santa Monica.
Transcript
You are presenting data on the adverse events associated with teprotumumab. What did you find?
I think this is an extremely important question, especially since it concerns patient safety. Now, if you look at the original trials, the most common side effects related to headaches, fatigue, muscle cramps. And these were easily dealt with adequate hydration and rest. And on the other side of the spectrum, they also found that patients with diabetes had a propensity to increase the glucose levels once they've been treated with teprotumumab. Now, once again, with careful monitoring a lot of the serious sort of outcomes of this are circumvented and in my experience, good management of these patients means that the glucose levels, even if they do spike, are easily caught and managed on the spot.
Now, one of the other adverse events that seems to be interesting is disturbances in hearing there have been a few patients that have experienced tinnitus following treatment with teprotumumab. And at this stage, most conditions have been found to be reversible. There have been a few instances where patients have had more long-term hearing disturbance, but it remains unclear if they had hearing disturbances to begin with before treatment. So, to look into this in more detail, we've designed some studies that will prospectively look at hearing disturbance to try and see the full incidence and prevalence in patients treated with teprotumumab.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
